Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...
bovnews54m
Gilead Sciences Inc (GILD) Reported a 37.45% Operating Margin Last Year—What’s the Real Story?
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...